SEK 12.69
-0.20 (-1.55%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SANION.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 5 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)NCT05147415Body weight (%)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients | Other: Placebo · Drug: Tesomet | Hypothalamic Obesity | 0 | 2022-12-09actual | 2022-12-13 |
| Study of Tesomet With Open-label Extension in Subjects With Prader-Willi SyndromeNCT05198362HyperphagiaRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients | Other: Placebo · Drug: Tesomet | Prader-Willi Syndrome | 0 | 2022-12-09actual | 2022-12-13 |
| First-in-human Study of SAN711 in Healthy ParticipantsNCT04971135Treatment-emergent Adverse Events (TEAEs) [SAD]Randomized · Quadruple-masked · Other | Phase 1 | Unknown status | Drug: SAN711 · Other: Placebo | Healthy | 80 | Jun 2022 | 2021-07-21 |
| 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)NCT03845075results2024-02-13Number of Participants With Treatment Emergent Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tesofensine/Metoprolol, Placebo | Hypothalamic Injury-induced Obesity (HIO) | 21 | 2020-10-16actual | 2024-02-13 |
| Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)NCT03149445results2024-02-26Percent Change From Baseline to End of Treatment in Mean Body WeightRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tesofensine/Metoprolol, Placebos | Confirmed Genetic Diagnosis of Prader-Willi Syndrome | 18 | 2019-07-22actual | 2024-02-26 |
| A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart RateNCT03488719results2024-02-09Dose of Metoprolol Resulting in no Change in Mean Heart Rate Over 24 Hours (M24HR)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Metoprolol Succinate 25 MG, Metoprolol Succinate 50 MG, Metoprolol Succinate 100 MG | Phase 1 | 37 | 2019-06-06actual | 2024-02-09 |
| Study to Investigate the Pharmacokinetic ProfileNCT03286829results2020-05-14AUC0-48Randomized · Single-masked · OtherStudy Protocol ↗ · Informed Consent Form ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Tesomet "High dose" in fasted condition, Tesomet "Low dose" in fasted condition, Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition., Tesomet "High dose" in fed condition | Healthy Male Subjects | 60 | 2018-02-06actual | 2020-05-14 |
| Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes MellitusNCT02737891results2020-05-14Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart RateRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tesofensine/Metoprolol, Placebo | Type 2 Diabetes Mellitus | 60 | Jan 2017actual | 2020-05-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19